3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
1
Conditions
Leukemia, Myeloid, Acute
2
Triple Negative Breast Neoplasms
1
Smoldering Multiple Myeloma
1
Sarcoma
1
Myelodysplastic Syndromes
1
Metastasis From Malignant Tumor of Kidney (Disorder)
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Cytarabine
358
Cyclophosphamide
241
Azacitidine
213
fludarabine phosphate
199
venetoclax
198
fludarabine
196
Busulfan
148
Decitabine
132
Mycophenolic Acid
123
Whole-Body Irradiation
122
Peripheral Blood Stem Cell Transplantation
118
Tacrolimus
115
Granulocyte Colony-Stimulating Factor
104
Idarubicin
100
Filgrastim
100
Melphalan
89
Cyclosporine
89
Methotrexate
83
Daunorubicin
76
Antilymphocyte Serum
75
Etoposide
73
Mitoxantrone
67
Clofarabine
67
Gemtuzumab
59
Stem Cell Transplantation
55
Thiotepa
51
Cladribine
46
Injections
45
Specimen Handling
44
thymoglobulin
40
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Leukemia, Myeloid, Acute
×
Immunotherapy, Active
×
Clear all
NCT07551037
2026-05-01
AML
Fujian Medical University Union Hospital
Phase 1
Recruiting
90 enrolled
NCT01819558
2015-03-20
ALLO-WT1
Institut Paoli-Calmettes
Phase 1/2
Completed
2 enrolled